Page last updated: 2024-12-05

n-methyl-d-glucamine dithiocarbamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-methyl-D-glucamine dithiocarbamate (MGD) is a water-soluble, highly potent, and selective inhibitor of nitric oxide synthase (NOS). It has been shown to effectively inhibit both inducible NOS (iNOS) and neuronal NOS (nNOS) in various studies. The compound's selectivity for NOS inhibition makes it a valuable tool for investigating the role of NO in various physiological and pathological processes. MGD is synthesized through a reaction between N-methyl-D-glucamine and carbon disulfide. It is important to note that MGD is not a drug approved for clinical use. However, its potential as a therapeutic agent for conditions associated with NOS dysfunction is being explored in preclinical studies. Research on MGD focuses on its therapeutic applications, including inflammation, stroke, and cancer. The compound's ability to modulate NO production, a key signaling molecule involved in various cellular processes, makes it a promising target for further investigation. '

N-methyl-D-glucamine dithiocarbamate: antidote for cadmium intoxication; repeated administration can result in reduction in cadmium levels of kidney & liver; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4181
SCHEMBL ID12359360
MeSH IDM0122446

Synonyms (3)

Synonym
n-methyl-d-glucamine dithiocarbamate
SCHEMBL12359360
PD160016

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" An examination of the dose-response curve for the suppression of cis-platinum nephrotoxicity by NaG shows that this can be achieved with mole ratios of NaG: cis-platinum as low as 1:1 given after appropriate pretreatment."( Control of some aspects of cis-platinum nephrotoxicity.
Basinger, MA; Craft, WD; Domingo, JL; Jones, MM; Llobet, JM, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (23.44)18.7374
1990's25 (39.06)18.2507
2000's21 (32.81)29.6817
2010's2 (3.13)24.3611
2020's1 (1.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.47 (24.57)
Research Supply Index4.22 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other67 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]